NCT06982079View on ClinicalTrials.gov

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

November 1, 2026

Conditions
Chronic Kidney Disease Stage 5CKD Stage 4
Interventions
DRUG

Dapagliflozin 10 mg

Dapagliflozin 10 mg will be added in addition to standard of care

Trial Locations (1)

Unknown

RECRUITING

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER